Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Furen Dai, Pingping Zhao
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process
10.1016/s0140-6736(26)00717-8 · 2026
Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome
10.1093/ejendo/lvad096 · 2023
The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis
10.1093/humrep/dew218 · 2016
Changes in the prevalence of polycystic ovary syndrome in China over the past decade
10.1016/j.lanwpc.2022.100494 · 2022
Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis
10.1093/humupd/dmaa029 · 2020
Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis
10.1210/jc.2013-2374 · 2013
Metformin and combined oral contraceptive pills in the management of polycystic ovary syndrome: a systematic review and meta-analysis
10.1210/clinem/dgad465 · 2024
Barriers and facilitators to the implementation of evidence-based lifestyle management in polycystic ovary syndrome: a narrative review
10.3390/medsci7070076 · 2019
openalex
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
Evidence-based lifestyle guidelines and self-management strategies utilized by women with polycystic ovary syndrome
10.3390/nu15030589 · 2023
Revised estimates for the number of human and bacteria cells in the body
10.1371/journal.pbio.1002533 · 2016
Gut microbiota: a hidden player in polycystic ovary syndrome
10.1186/s12967-025-06315-7 · 2025
Intersection of polycystic ovary syndrome and the gut microbiome
10.1210/jendso/bvaa177 · 2021
From gut to hormones: unraveling the role of gut microbiota in (phyto) estrogen modulation in health and disease
10.1002/mnfr.202300688 · 2024
Androgen-induced gut dysbiosis disrupts glucolipid metabolism and endocrinal functions in polycystic ovary syndrome
10.1186/s40168-021-01046-5 · 2021
The effects of ketonemia on the course of epilepsy
1921
Ketogenic diet: a review of composition diversity, mechanism of action and clinical application
10.1155/2024/6666171 · 2024
Beneficial effects of the ketogenic diet in metabolic syndrome: a systematic review
10.3390/diabetology3020020 · 2022
Why a d-β-hydroxybutyrate monoester?
10.1042/bst20190240 · 2020
GDF15 is a major determinant of ketogenic diet-induced weight loss
10.1016/j.cmet.2023.11.003 · 2023
Effects of a ketogenic diet in overweight women with polycystic ovary syndrome
10.1186/s12967-020-02277-0 · 2020
A ketogenic diet followed by gradual carbohydrate reintroduction restores menstrual cycles in women with polycystic ovary syndrome with oligomenorrhea independent of body weight loss: results from a single-center, one-arm, pilot study
10.3390/metabo14120691 · 2024
The international scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic
10.1038/nrgastro.2014.66 · 2014
The effect of probiotics on the production of short-chain fatty acids by human intestinal microbiome
10.3390/nu12041107 · 2020
Mechanisms of action of probiotics
10.1093/advances/nmy063 · 2019
Effects of probiotics, prebiotics, and synbiotics on polycystic ovary syndrome: a systematic review and meta-analysis
10.1080/10408398.2021.1951155 · 2023
Lactiplantibacillus plantarum CCFM1019 attenuate polycystic ovary syndrome through butyrate dependent gut–brain mechanism
10.1039/d1fo01744f · 2022
Perturbations in gut microbiota composition in patients with polycystic ovary syndrome: a systematic review and meta-analysis
10.1186/s12916-023-02975-8 · 2023
Dysbiotic alteration in the fecal microbiota of patients with polycystic ovary syndrome
10.1128/spectrum.04291-23 · 2024
Metagenomic analysis identified microbiome alterations and pathological association between intestinal microbiota and polycystic ovary syndrome
10.1016/j.fertnstert.2020.01.027 · 2020
Gut microbiome in PCOS associates to serum metabolomics: a cross-sectional study
10.1038/s41598-022-25041-4 · 2022
The gut microbial composition in polycystic ovary syndrome with insulin resistance: findings from a normal-weight population
10.1186/s13048-021-00799-9 · 2021
Gut microbiota–bile acid–interleukin-22 axis orchestrates polycystic ovary syndrome
10.1038/s41591-019-0509-0 · 2019
The gut microbial composition in polycystic ovary syndrome with hyperandrogenemia and its association with steroid hormones
10.3389/fcell.2024.1384233 · 2024
Causal relationship between gut microbiota and polycystic ovary syndrome: a literature review and Mendelian randomization study
10.3389/fendo.2024.1280983 · 2024
Causal association between gut microbiome and polycystic ovary syndrome: a bidirectional Mendelian randomization study
10.29063/ajrh2024/v28i12.14 · 2024
Causal relationships between gut microbiota and polycystic ovarian syndrome: a bidirectional Mendelian randomization study
2024
Fecal microbiota transplantation from patients with polycystic ovary syndrome induces metabolic disorders and ovarian dysfunction in germ-free mice
10.1186/s12866-024-03513-z · 2024
Exposure to a healthy gut microbiome protects against reproductive and metabolic dysregulation in a PCOS mouse model
10.1210/en.2019-00050 · 2019
Prenatal androgen exposure causes hypertension and gut microbiota dysbiosis
10.1080/19490976.2018.1441664 · 2018
Clostridium scindens: a human gut microbe with a high potential to convert glucocorticoids into androgens
10.1194/jlr.m038869 · 2013
Gut microbiota dysbiosis in polycystic ovary syndrome: focus on diet, probiotics, and traditional Chinese medicine
10.3389/fmicb.2025.1659783 · doi-reference
Gut microbiota, a new approach to management of polycystic ovary syndrome: a systematic review, meta-analysis and meta-evidence of 26 randomized controlled trials
10.1186/s13048-025-01959-x · doi-reference
The role of lifestyle interventions in PCOS management: a systematic review
10.3390/nu17020310 · doi-reference
The microbial metabolite agmatine acts as an FXR agonist to promote polycystic ovary syndrome in female mice
10.1038/s42255-024-01041-8 · doi-reference
Effects of supplementation with two probiotic strains (Lactobacillus helveticus and Bifidobacterium longum) on hormonal status, oxidative stress, and clinical symptoms in women with polycystic ovary syndrome: a randomized clinical trial
10.1186/s12937-025-01240-3 · doi-reference
Six-month randomized, placebo controlled trial of synbiotic supplementation in women with polycystic ovary syndrome undergoing lifestyle modifications
10.1007/s00404-024-07833-3 · doi-reference
Changes in hormonal profile and body mass index in women with polycystic ovary syndrome after probiotic intake: a 12-week placebo-controlled and randomized clinical study
10.3390/nu17030405 · doi-reference
The effects of probiotic and selenium co-supplementation on parameters of mental health, hormonal profiles, and biomarkers of inflammation and oxidative stress in women with polycystic ovary syndrome
10.1186/s13048-018-0457-1 · doi-reference
Effect of probiotics combined with metformin on improvement of menstrual and metabolic patterns in women with polycystic ovary syndrome: a randomized clinical trial
10.1080/09513590.2022.2119219 · doi-reference
The probiotic supplementation reduced inflammation in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial
10.1016/j.jff.2017.12.047 · doi-reference
Akkermansia muciniphila PROBIO therapy promotes arginine biosynthesis and reverses reproductive impairments in polycystic ovary syndrome rats
10.1007/s11684-025-1161-3 · doi-reference
Gut metabolites are more predictive of disease and cohoused states than gut bacterial features in a polycystic ovary syndrome-like mouse model
10.1128/msystems.01149-20 · doi-reference
Dysbiosis of gut microbiota associated with clinical parameters in polycystic ovary syndrome
10.3389/fmicb.2017.00324 · doi-reference
Lactic acid bacteria alleviate polycystic ovarian syndrome by regulating sex hormone related gut microbiota
10.1039/c9fo02554e · doi-reference
Association between polycystic ovary syndrome and gut microbiota
10.1371/journal.pone.0153196 · doi-reference
Synbiotic supplementation improves metabolic factors and obesity values in women with polycystic ovary syndrome independent of affecting apelin levels: a randomized double-blind placebo-controlled clinical trial
10.22074/ijfs.2021.6186 · doi-reference
Probiotic Bifidobacterium lactis V9 regulates the secretion of sex hormones in polycystic ovary syndrome patients through the gut-brain axis
10.1128/msystems.00017-19 · doi-reference
A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice
10.1038/nm.4236 · doi-reference
The influence of Akkermansia muciniphila on intestinal barrier function
10.1186/s13099-024-00635-7 · doi-reference
Ketogenic diet aggravates colitis, impairs intestinal barrier and alters gut microbiota and metabolism in DSS-induced mice
10.1039/d1fo02288a · doi-reference
Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis
10.1016/j.fertnstert.2010.11.036 · doi-reference
Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy
10.1152/ajpgi.00223.2019 · doi-reference
Intestinal microbiota-derived short-chain fatty acids regulation of immune cell IL-22 production and gut immunity
10.1038/s41467-020-18262-6 · doi-reference
Ketogenic diets alter the gut microbiome resulting in decreased intestinal Th17 cells
10.1016/j.cell.2020.04.027 · doi-reference
Very low-calorie ketogenic diet: a safe and effective tool for weight loss in patients with obesity and mild kidney failure
10.3390/nu12020333 · doi-reference
The effects of portfolio moderate-carbohydrate and ketogenic diets on anthropometric indices, metabolic status, and hormonal levels in overweight or obese women with polycystic ovary syndrome: a randomized controlled trial
10.1186/s12937-024-01056-7 · doi-reference
The effects of a low-carbohydrate, ketogenic diet on the polycystic ovary syndrome: a pilot study
10.1186/1743-7075-2-35 · doi-reference
The AMPK signalling pathway coordinates cell growth, autophagy and metabolism
10.1038/ncb2329 · doi-reference
AMP-activated protein kinase: maintaining energy homeostasis at the cellular and whole-body levels
10.1146/annurev-nutr-071812-161148 · doi-reference
Impact of ketosis on appetite regulation—a review
10.1016/j.nutres.2020.02.010 · doi-reference
Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment
10.1186/s13048-022-01091-0 · doi-reference
Effects of ketogenic diets on polycystic ovary syndrome: a systematic review and meta-analysis
10.1186/s12958-025-01411-1 · doi-reference
Modified Atkins diet with slow reduction of carbohydrate
10.1016/j.ebr.2019.100353 · doi-reference
European guidelines for obesity management in adults with a very low-calorie ketogenic diet: a systematic review and meta-analysis
10.1159/000515381 · doi-reference
Optimal clinical management of children receiving dietary therapies for epilepsy: updated recommendations of the international ketogenic diet study group
10.1002/epi4.12225 · doi-reference
Journey through the gut-inflammation axis in polycystic ovary syndrome: the microbiota’s role in shaping inflammatory pathways
10.1007/s11010-025-05409-6 · doi-reference
Gut-ovary axis in polycystic ovary syndrome: mechanistic insights and gut microbiota-targeted therapeutic strategies
10.3389/fendo.2025.1684492 · doi-reference
Clinical and microbiological changes during pregnancy in women with congenital heart defects
10.17816/jowd701582 · doi-reference
Metabolic disorders in polycystic ovary syndrome: from gut microbiota biodiversity to clinical intervention
10.3389/fendo.2025.1526468 · doi-reference
Estrogen–gut microbiome axis: physiological and clinical implications
10.1016/j.maturitas.2017.06.025 · doi-reference